InflaRx

$3.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (+5.01%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell InflaRx and other stocks, options, and ETFs commission-free!

About IFRX

InflaRx N.V. Common Stock, also called InflaRx, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany. The listed name for IFRX is InflaRx N.V. Common Stock.

CEO
Niels Christoph Riedemann
Employees
45
Headquarters
Jena, Thueringen
Founded
2007
Market Cap
110.48M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
667.73K
High Today
$4.01
Low Today
$3.55
Open Price
$3.90
Volume
426.54K
52 Week High
$9.70
52 Week Low
$2.52

IFRX Earnings

-$0.65
-$0.43
-$0.22
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Apr 28, Pre-Market

You May Also Like

CAPA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure